title: Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.
abstract: The pleiotropic cytokine tumor necrosis factor-alpha (TNF-alpha) and thrombin lead to increased endothelial permeability in sepsis. Numerous studies demonstrated the significance of intracellular cyclic nucleotides for the maintenance of endothelial barrier function. Actions of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are terminated by distinct cyclic nucleotide phosphodiesterases (PDEs). We hypothesized that TNF-alpha could regulate PDE activity in endothelial cells, thereby impairing endothelial barrier function. In cultured human umbilical vein endothelial cells (HUVECs), we found a dramatic increase of PDE2 activity following TNF-alpha stimulation, while PDE3 and PDE4 activities remained unchanged. Significant PDE activities other than PDE2, PDE3, and PDE4 were not detected. TNF-alpha increased PDE2 expression in a p38 mitogen-activated protein kinase (MAPK)-dependent manner. Endothelial barrier function was investigated in HUVECs and in isolated mice lungs. Selective PDE2 up-regulation sensitized HUVECs toward the permeability-increasing agent thrombin. In isolated mice lungs, we demonstrated that PDE2 inhibition was effective in preventing thrombin-induced lung edema, as shown with a reduction in both lung wet-to-dry ratio and albumin flux from the vascular to bronchoalveolar compartment. Our findings suggest that TNF-alpha-mediated up-regulation of PDE2 may destabilize endothelial barrier function in sepsis. Inhibition of PDE2 is therefore of potential therapeutic interest in sepsis and acute respiratory distress syndrome (ARDS).
authors.affiliation: Charité Universitätsmedizin Berlin, Humboldt-University, Department of Internal Medicine/Infectious Diseases, Augustenburger Platz 1, 13353 Berlin, Germany. joachim.seybold@charite.de
authors.forename: Joachim
authors.initials: J
authors.lastname: Seybold
authors.forename: Dirk
authors.initials: D
authors.lastname: Thomas
authors.forename: Martin
authors.initials: M
authors.lastname: Witzenrath
authors.forename: Sengül
authors.initials: S
authors.lastname: Boral
authors.forename: Andreas C
authors.initials: AC
authors.lastname: Hocke
authors.forename: Alexander
authors.initials: A
authors.lastname: Bürger
authors.forename: Armin
authors.initials: A
authors.lastname: Hatzelmann
authors.forename: Hermann
authors.initials: H
authors.lastname: Tenor
authors.forename: Christian
authors.initials: C
authors.lastname: Schudt
authors.forename: Matthias
authors.initials: M
authors.lastname: Krüll
authors.forename: Hartwig
authors.initials: H
authors.lastname: Schütte
authors.forename: Stefan
authors.initials: S
authors.lastname: Hippenstiel
authors.forename: Norbert
authors.initials: N
authors.lastname: Suttorp
mesh_terms: D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2; D004487:Edema / Q000139:chemically induced; D004730:Endothelium, Vascular / Q000166:cytology* / Q000201:enzymology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D010727:Phosphoric Diester Hydrolases / Q000235:genetics* / Q000378:metabolism; D018805:Sepsis / Q000473:pathology; D013917:Thrombin / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D014471:Umbilical Veins / Q000166:cytology; D015854:Up-Regulation / Q000187:drug effects* / Q000235:genetics; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D014409:Tumor Necrosis Factor-alpha; D048051:p38 Mitogen-Activated Protein Kinases; D010727:Phosphoric Diester Hydrolases; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2; C517275:PDE2A protein, human; C517277:Pde2a protein, mouse; D013917:Thrombin